Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Saraswathisreeram Pranush Kumar, Deeki Doma Sherpa, Amit Kumar Sahu, Tarang Jadav, Rakesh Kumar Tekade & Pinaki Sengupta. (2021) Innovation in Bioanalytical Strategies and in vitro Drug–drug Interaction Study Approaches in Drug Discovery. Bioanalysis 13:6, pages 513-532.
Read now
Read now
Fawzy A El-Yazbi, Omayma A Amin, Eman I El-Kimary, Essam F Khamis, Sameh E Younis, Mohammed A W Elkhatib & Ahmed F El-Yazbi. (2019) A Novel HPLC-DAD Method for Simultaneous Determination of Febuxostat and Diclofenac in Biological Samples: Pharmacokinetic Outcomes. Bioanalysis 11:1, pages 41-54.
Read now
Read now
Sandra Pamela Chinchilla, Irati Urionaguena & Fernando Perez-Ruiz. (2016) Febuxostat for the chronic management of hyperuricemia in patients with gout. Expert Review of Clinical Pharmacology 9:5, pages 665-673.
Read now
Read now
Harmanjot K Grewal, Joseph R Martinez & Luis R Espinoza. (2014)
Febuxostat: drug review and update. Expert Opinion on Drug Metabolism & Toxicology 10:5, pages 747-758.
Read now
Read now
Kapendra Sahu, Anees A Siddiqui, Mohammad Shaharyar & Sachin Malik. (2014) Pharmacokinetic interaction between febuxostat and morin in rats. Expert Opinion on Drug Metabolism & Toxicology 10:3, pages 307-312.
Read now
Read now
Lada Beara-Lasic, Michael H Pillinger & David S Goldfarb. (2010) Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia. International Journal of Nephrology and Renovascular Disease 3, pages 1-10.
Read now
Read now
Miao Hu & Brian Tomlinson. (2008) Febuxostat in the management of hyperuricemia and chronic gout: a review. Therapeutics and Clinical Risk Management 4:6, pages 1209-1220.
Read now
Read now
Articles from other publishers (40)
Yasushi Yamazoe, Yoshiya Yamamura & Kouichi Yoshinari. (2024) Construction of a fused grid-based CYP2C8-Template system and the application. Drug Metabolism and Pharmacokinetics 55, pages 100492.
Crossref
Crossref
Hisataka Itoh, Naho Yamashita, Shinobu Kamijo, Kazufumi Masuda, Hisato Kato & Satoshi Yamaori. (2023) Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chemico-Biological Interactions 382, pages 110644.
Crossref
Crossref
Jeong-Eun Yu, Byoung Hoon You, Mingoo Bae, Seung Yon Han, Kiwon Jung & Young Hee Choi. (2023) Evaluation of Pharmacokinetic Feasibility of Febuxostat/L-pyroglutamic Acid Cocrystals in Rats and Mice. Pharmaceutics 15:8, pages 2167.
Crossref
Crossref
Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf & V. Sashi Gopaul. (2023) Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans. Drug Metabolism and Disposition 51:4, pages 451-463.
Crossref
Crossref
Meijuan Xu, Ying Chen, Xiaoyun Xi, Chao Jiang, Qian Zhang, Ting Wu, Jihong Chu, Guoliang Dai, Yongtao Bai, Qian Yu, Jiandong Zou & Wenzheng Ju. (2022) In vitro inhibitory effects of components from Salvia miltiorrhiza on catalytic activity of three human Arachidonic acid ω-hydroxylases. Drug Metabolism and Pharmacokinetics 43, pages 100402.
Crossref
Crossref
Muxuan Wang, Jiashu Chen, Ruirui Zhang, Xinyan Guo, Daxia Chen, Xu Guo, Yingying Chen, Yuhao Wu, Jinyue Sun, Yufa Liu & Chao Liu. (2021) Design, synthesis and bioactive evaluation of geniposide derivatives for antihyperuricemic and nephroprotective effects. Bioorganic Chemistry 116, pages 105321.
Crossref
Crossref
Lei Feng, Jing Ning, Xiangge Tian, Chao Wang, Zhenlong Yu, Xiaokui Huo, Tian Xie, Baojing Zhang, Tony D. James & Xiaochi Ma. (2021) Fluorescent probes for the detection and imaging of Cytochrome P450. Coordination Chemistry Reviews 437, pages 213740.
Crossref
Crossref
Bishoy Kamel, Garry G. Graham, Sophie L. Stocker, Zhixin Liu, Kenneth M. Williams, Jane E. Carland, Kevin D. Pile & Richard O. Day. (2020) A pharmacokinetic‐pharmacodynamic study of a single dose of febuxostat in healthy subjects. British Journal of Clinical Pharmacology 86:12, pages 2486-2496.
Crossref
Crossref
Minna Lehtisalo, Jenni E. Keskitalo, Aleksi Tornio, Outi Lapatto‐Reiniluoto, Feng Deng, Taina Jaatinen, Jenni Viinamäki, Mikko Neuvonen, Janne T. Backman & Mikko Niemi. (2020) Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. Clinical and Translational Science 13:6, pages 1236-1243.
Crossref
Crossref
Hitomi Komatsu, Mariko Enomoto, Hisashi Shiraishi, Yasuyo Morita, Daisuke Hashimoto, Shuichi Nakayama, Shogo Funakoshi, Seiki Hirano, Yoshio Terada, Mitsuhiko Miyamura & Shimpei Fujimoto. (2020) Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes. Diabetology International 11:4, pages 388-392.
Crossref
Crossref
Dong-Gyun Han, Kyu-Sang Kim, Seong-Wook Seo, Young Mee Baek, Yunjin Jung, Dae-Duk Kim & In-Soo Yoon. (2020)
A sensitive HPLC-FL method to simultaneously determine febuxostat and diclofenac in rat plasma: assessment of metabolic drug interactions
in vitro
and
in vivo
. Analytical Methods 12:16, pages 2166-2175.
Crossref
Crossref
Yun‐Shiuan O. Hsu, I‐Wen Wu, Shang‐Hung Chang, Cheng‐Chia Lee, Chung‐Ying Tsai, Chan‐Yu Lin, Wan‐Ting Lin, Yu‐Tung Huang, Chao‐Yi Wu, George Kuo, Chih‐Yen Hsiao, Hsing‐Lin Lin, Chih‐Chao Yang, Tzung‐Hai Yen, Yung‐Chang Chen, Cheng‐Chieh Hung, Ya‐Chong Tian, Chang‐Fu Kuo, Chih‐Wei Yang, Gerard F. Anderson & Huang‐Yu Yang. (2019) Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis. Clinical Pharmacology & Therapeutics 107:5, pages 1159-1169.
Crossref
Crossref
Yasushi Yamazoe & Kouichi Yoshinari. (2020) Prediction of regioselectivity and preferred order of CYP1A1-mediated metabolism: Solving the interaction of human and rat CYP1A1 forms with ligands on the template system. Drug Metabolism and Pharmacokinetics 35:1, pages 165-185.
Crossref
Crossref
Kenji Ikemura, Shun-ichi Hiramatsu, Yuri Shinogi, Yusuke Nakatani, Isao Tawara, Takuya Iwamoto, Naoyuki Katayama & Masahiro Okuda. (2019) Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein. Scientific Reports 9:1.
Crossref
Crossref
Vicky Tai, Tony R. Merriman & Nicola Dalbeth. (2019) Genetic advances in gout: potential applications in clinical practice. Current Opinion in Rheumatology 31:2, pages 144-151.
Crossref
Crossref
Jesse Hall, Michael Gillen, Xiaojuan Yang & Zancong Shen. (2018) Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers. Clinical Pharmacology in Drug Development 8:2, pages 179-187.
Crossref
Crossref
Eeunyoung AhnSunggun LeeHan-Na LeeSeung-Geun LeeMin Wook So. (2019) Comparison of Efficacy and Safety of Febuxostat in Gout Patients with Chronic Kidney Disease Stage 3 and Stage 4/5. Journal of Rheumatic Diseases 26:2, pages 118.
Crossref
Crossref
M. S. Petrova, М. M. Musiychuk & V. I. Mazurov. (2018) The current treatment strategy for gouty arthritis. Modern Rheumatology Journal 12:3, pages 70-75.
Crossref
Crossref
Satoshi Yamaori, Noriyuki Araki, Mio Shionoiri, Kurumi Ikehata, Shinobu Kamijo, Shigeru Ohmori & Kazuhito Watanabe. (2018) A Specific Probe Substrate for Evaluation of CYP4A11 Activity in Human Tissue Microsomes and a Highly Selective CYP4A11 Inhibitor: Luciferin-4A and Epalrestat. Journal of Pharmacology and Experimental Therapeutics 366:3, pages 446-457.
Crossref
Crossref
Pierre-Antoine Juge, Marie-Elise Truchetet, Evangeline Pillebout, Sébastien Ottaviani, Cécile Vigneau, Clotilde Loustau, Divi Cornec, Tristan Pascart, Renaud Snanoudj, Florian Bailly, Emilie Cornec-Le Gall, Thierry Schaeverbeke, Alain Saraux, Philippe Dieudé, René-Marc Flipo, Pascal Richette, Frédéric Lioté, Thomas Bardin, Gérard Chalès & Hang-Korng Ea. (2018) Efficacité et tolérance du fébuxostat chez 73 patients goutteux avec une insuffisance rénale chronique stade 4/5 : étude rétrospective de 10 centres. Revue du Rhumatisme 85:4, pages 370-374.
Crossref
Crossref
Pierre-Antoine Juge, Marie-Elise Truchetet, Evangeline Pillebout, Sébastien Ottaviani, Cécile Vigneau, Clotilde Loustau, Divi Cornec, Tristan Pascart, Renaud Snanoudj, Florian Bailly, Emilie Cornec-Le Gall, Thierry Schaeverbeke, Alain Saraux, Philippe Dieudé, René-Marc Flipo, Pascal Richette, Frédéric Lioté, Thomas Bardin, Gérard Chalès & Hang-Korng Ea. (2017) Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine 84:5, pages 595-598.
Crossref
Crossref
Bishoy Kamel, Garry G. Graham, Kenneth M. Williams, Kevin D. Pile & Richard O. Day. (2016) Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. Clinical Pharmacokinetics 56:5, pages 459-475.
Crossref
Crossref
Meihua Lin, Jian Liu, Huili Zhou, Minglan Wu, Duo Lv, Yujie Huang, Yunliang Zheng, Jianzhong Shentu & Lihua Wu. (2017) Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers. Drug Metabolism and Pharmacokinetics 32:1, pages 77-84.
Crossref
Crossref
Hiroyoshi Koide, Daiki Hira, Masayuki Tsujimoto, Yurie Katsube, Tetsuya Minegaki, Takashi Uzu, Yoshito Ikeda, Shin-ya Morita, Kohshi Nishiguchi & Tomohiro Terada. (2017) Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 40:5, pages 681-686.
Crossref
Crossref
Janne T. Backman, Anne M. Filppula, Mikko Niemi & Pertti J. Neuvonen. (2015) Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews 68:1, pages 168-241.
Crossref
Crossref
Huiru Xie, Zhijun Wang, Ke Deng, Xuehua Jiang, Ling Wang & Guoyu Lv. (2014) An HPLC–MS/MS method for simultaneous determination of the active metabolites of febuxostat (67M-1, 67M-2 and 67M-4) in human plasma. Journal of Chromatography B 970, pages 24-30.
Crossref
Crossref
Lisa K. Stamp & Peter T. Chapman. (2014) Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout. Drugs & Aging 31:11, pages 777-786.
Crossref
Crossref
Y. Kang, M. J. Kim, H. N. Jang, E. J. Bae, S. Yun, H. S. Cho, S.-H. Chang & D. J. Park. (2014) Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease. Journal of Clinical Pharmacy and Therapeutics 39:3, pages 328-330.
Crossref
Crossref
Jiangbo Du. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
4
.
Robert T. Keenan. (2012) Safety of Urate-Lowering Therapies. Rheumatic Disease Clinics of North America 38:4, pages 663-680.
Crossref
Crossref
Nicola Dalbeth & Lisa K. Stamp. 2012. Gout & Other Crystal Arthropathies. Gout & Other Crystal Arthropathies
154
173
.
Victoria M Kelly & Eswar Krishnan. (2011) Febuxostat for the treatment of hyperuricemia in patients with gout. International Journal of Clinical Rheumatology 6:5, pages 485-493.
Crossref
Crossref
Lisa K. Stamp & Sarah Jordan. (2011) The Challenges of Gout Management in the Elderly. Drugs & Aging 28:8, pages 591-603.
Crossref
Crossref
Charnelda L. Gray & Nafesa E. Walters-Smith. (2011) Febuxostat for treatment of chronic gout. American Journal of Health-System Pharmacy 68:5, pages 389-398.
Crossref
Crossref
Yoshiyuki Yamaura, Kouichi Yoshinari & Yasushi Yamazoe. (2011) Predicting Oxidation Sites with Order of Occurrence among Multiple Sites for CYP4A-mediated Reactions. Drug Metabolism and Pharmacokinetics 26:4, pages 351-363.
Crossref
Crossref
Christopher M Burns & Robert L Wortmann. (2011) Gout therapeutics: new drugs for an old disease. The Lancet 377:9760, pages 165-177.
Crossref
Crossref
Bryan L. Love, Robert Barrons, Angie Veverka & K. Matthew Snider. (2012) Urate‐Lowering Therapy for Gout: Focus on Febuxostat. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30:6, pages 594-608.
Crossref
Crossref
Michael E. Ernst & Michelle A. Fravel. (2009) Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clinical Therapeutics 31:11, pages 2503-2518.
Crossref
Crossref
Fernando Perez-Ruiz, Nicola Dalbeth & Naomi Schlesinger. (2008) Febuxostat, a novel drug for the treatment of hyperuricemia of gout. Future Rheumatology 3:5, pages 421-427.
Crossref
Crossref
Philip I Hair, Paul L McCormack & Gillian M Keating. (2008) Febuxostat. Drugs 68:13, pages 1865-1874.
Crossref
Crossref